Relevant SARS‐CoV‐2 viremia is associated with COVID‐19 severity: Prospective cohort study and validation cohort
Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐...
Saved in:
Published in: | Journal of medical virology Vol. 94; no. 11; pp. 5260 - 5270 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Wiley Subscription Services, Inc
01-11-2022
John Wiley and Sons Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort.
Summary
Evaluation of SARS‐CoV‐2 viral load kinetics in plasma assessed by quantitative RT‐PCR as an indicator of poor prognosis in hospitalized COVID‐19 patients. |
---|---|
AbstractList | Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort. Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV ( N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), ( p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort. Evaluation of SARS‐CoV‐2 viral load kinetics in plasma assessed by quantitative RT‐PCR as an indicator of poor prognosis in hospitalized COVID‐19 patients. Early kinetics of SARS-CoV-2 viral load (VL) in plasma determined by quantitative reverse-transcription polymerase chain reaction (RT-PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single-center study including consecutive adult patients hospitalized with COVID-19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT-PCR was performed to assess SARS-CoV-2 VL. The main outcomes were in-hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID-19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU-admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1-15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3-28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8-22]; p < 0.0001). Relevant SARS-CoV-2 viremia in the first week of hospitalization was associated with higher in-hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort. Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV (N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), (p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort. Summary Evaluation of SARS‐CoV‐2 viral load kinetics in plasma assessed by quantitative RT‐PCR as an indicator of poor prognosis in hospitalized COVID‐19 patients. |
Author | Rodríguez García, Sebastián C. Sanz García, Ancor Quicios, Begoña Arribas, David Marcos, Celeste Patiño, Pablo Rodríguez‐Serrano, Diego A. García‐Vicuña, Rosario Soriano, Joan B. Galván Román, José M. Cardeñoso Domingo, Laura Martín Ramírez, Alexandra Uriarte, Miren García Castillo, Elena Roy Vallejo, Emilia Sánchez Azofra, Ana Ortiz, Javier Muñoz Calleja, Cecilia Iturrate, Isabel Ancochea, Julio Villa, Almudena Trigueros, Marina Arévalo, Cristina Ávalos Pérez‐Urria, Elena Hernando Santos, Julia González, Begoña Canabal, Alfonso Suarez Fernández, Carmen Méndez, Rosa De la Cámara, Rafael Zurita Cruz, Nelly D. Chicot Llano, Marta Barrios, Ana Álvarez Rodríguez, Jesús Fontán García‐Rodrigo, Leticia Ciudad Sañudo, Marianela Triguero Martínez, Ana González Álvaro, Isidoro |
AuthorAffiliation | 6 Hematology Department Hospital Universitario La Princesa Madrid Spain 8 Methodology Unit. Health Research Institute. Hospital Universitario La Princesa IIS‐IP Madrid Spain 2 Internal Medicine Department Hospital Universitario La Princesa Madrid Spain 10 Present address: Intensive Care Unit, Hospital Universitario Príncipe de Asturias Alcalá de Henares Spain 3 Intensive Care Unit, Hospital Universitario La Princesa Madrid Spain 4 Pneumology Department Hospital Universitario La Princesa Madrid Spain 5 Anesthesiology Department Hospital Universitario La Princesa Madrid Spain 9 Immunology Department Hospital Universitario La Princesa Madrid Spain 1 Microbiology Department Hospital Universitario La Princesa Madrid Spain 7 Rheumathology Department Hospital Universitario La Princesa Madrid Spain |
AuthorAffiliation_xml | – name: 7 Rheumathology Department Hospital Universitario La Princesa Madrid Spain – name: 1 Microbiology Department Hospital Universitario La Princesa Madrid Spain – name: 2 Internal Medicine Department Hospital Universitario La Princesa Madrid Spain – name: 4 Pneumology Department Hospital Universitario La Princesa Madrid Spain – name: 6 Hematology Department Hospital Universitario La Princesa Madrid Spain – name: 10 Present address: Intensive Care Unit, Hospital Universitario Príncipe de Asturias Alcalá de Henares Spain – name: 3 Intensive Care Unit, Hospital Universitario La Princesa Madrid Spain – name: 5 Anesthesiology Department Hospital Universitario La Princesa Madrid Spain – name: 9 Immunology Department Hospital Universitario La Princesa Madrid Spain – name: 8 Methodology Unit. Health Research Institute. Hospital Universitario La Princesa IIS‐IP Madrid Spain |
Author_xml | – sequence: 1 givenname: Laura surname: Cardeñoso Domingo fullname: Cardeñoso Domingo, Laura email: lauramaria.cardenoso@salud.madrid.org, lacado@gmail.com organization: Hospital Universitario La Princesa – sequence: 2 givenname: Emilia surname: Roy Vallejo fullname: Roy Vallejo, Emilia organization: Hospital Universitario La Princesa – sequence: 3 givenname: Nelly D. surname: Zurita Cruz fullname: Zurita Cruz, Nelly D. organization: Hospital Universitario La Princesa – sequence: 4 givenname: Marta surname: Chicot Llano fullname: Chicot Llano, Marta organization: Hospital Universitario La Princesa – sequence: 5 givenname: Elena surname: Ávalos Pérez‐Urria fullname: Ávalos Pérez‐Urria, Elena organization: Hospital Universitario La Princesa – sequence: 6 givenname: Ana surname: Barrios fullname: Barrios, Ana organization: Hospital Universitario La Princesa – sequence: 7 givenname: Julia surname: Hernando Santos fullname: Hernando Santos, Julia organization: Hospital Universitario La Princesa – sequence: 8 givenname: Javier surname: Ortiz fullname: Ortiz, Javier organization: Hospital Universitario La Princesa – sequence: 9 givenname: Sebastián C. surname: Rodríguez García fullname: Rodríguez García, Sebastián C. organization: Hospital Universitario La Princesa – sequence: 10 givenname: Alexandra surname: Martín Ramírez fullname: Martín Ramírez, Alexandra organization: Hospital Universitario La Princesa – sequence: 11 givenname: Marianela surname: Ciudad Sañudo fullname: Ciudad Sañudo, Marianela organization: Hospital Universitario La Princesa – sequence: 12 givenname: Celeste surname: Marcos fullname: Marcos, Celeste organization: Hospital Universitario La Princesa – sequence: 13 givenname: Elena surname: García Castillo fullname: García Castillo, Elena organization: Hospital Universitario La Princesa – sequence: 14 givenname: Leticia surname: Fontán García‐Rodrigo fullname: Fontán García‐Rodrigo, Leticia organization: Hospital Universitario La Princesa – sequence: 15 givenname: Begoña surname: González fullname: González, Begoña organization: Hospital Universitario La Princesa – sequence: 16 givenname: Rosa surname: Méndez fullname: Méndez, Rosa organization: Hospital Universitario La Princesa – sequence: 17 givenname: Isabel surname: Iturrate fullname: Iturrate, Isabel organization: Hospital Universitario La Princesa – sequence: 18 givenname: Ancor surname: Sanz García fullname: Sanz García, Ancor organization: Hospital Universitario La Princesa – sequence: 19 givenname: Almudena surname: Villa fullname: Villa, Almudena organization: Hospital Universitario La Princesa – sequence: 20 givenname: Ana surname: Sánchez Azofra fullname: Sánchez Azofra, Ana organization: Hospital Universitario La Princesa – sequence: 21 givenname: Begoña surname: Quicios fullname: Quicios, Begoña organization: Hospital Universitario La Princesa – sequence: 22 givenname: David surname: Arribas fullname: Arribas, David organization: Hospital Universitario La Princesa – sequence: 23 givenname: Jesús surname: Álvarez Rodríguez fullname: Álvarez Rodríguez, Jesús organization: Hospital Universitario La Princesa – sequence: 24 givenname: Pablo surname: Patiño fullname: Patiño, Pablo organization: Hospital Universitario La Princesa – sequence: 25 givenname: Marina surname: Trigueros fullname: Trigueros, Marina organization: Hospital Universitario La Princesa – sequence: 26 givenname: Miren surname: Uriarte fullname: Uriarte, Miren organization: Hospital Universitario La Princesa – sequence: 27 givenname: Ana surname: Triguero Martínez fullname: Triguero Martínez, Ana organization: Hospital Universitario La Princesa – sequence: 28 givenname: Cristina surname: Arévalo fullname: Arévalo, Cristina organization: Hospital Universitario La Princesa – sequence: 29 givenname: José M. surname: Galván Román fullname: Galván Román, José M. organization: Hospital Universitario La Princesa – sequence: 30 givenname: Rosario surname: García‐Vicuña fullname: García‐Vicuña, Rosario organization: Hospital Universitario La Princesa – sequence: 31 givenname: Julio surname: Ancochea fullname: Ancochea, Julio organization: Hospital Universitario La Princesa – sequence: 32 givenname: Joan B. surname: Soriano fullname: Soriano, Joan B. organization: Hospital Universitario La Princesa – sequence: 33 givenname: Alfonso surname: Canabal fullname: Canabal, Alfonso organization: Hospital Universitario La Princesa – sequence: 34 givenname: Cecilia surname: Muñoz Calleja fullname: Muñoz Calleja, Cecilia organization: Hospital Universitario La Princesa – sequence: 35 givenname: Rafael surname: De la Cámara fullname: De la Cámara, Rafael organization: Hospital Universitario La Princesa – sequence: 36 givenname: Carmen surname: Suarez Fernández fullname: Suarez Fernández, Carmen organization: Hospital Universitario La Princesa – sequence: 37 givenname: Isidoro surname: González Álvaro fullname: González Álvaro, Isidoro organization: Hospital Universitario La Princesa – sequence: 38 givenname: Diego A. surname: Rodríguez‐Serrano fullname: Rodríguez‐Serrano, Diego A. organization: Hospital Universitario La Princesa |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35811284$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1u1DAQxy1URLeFAy-ALHGBQ1p_JbE5IFXLV1FRUQt7tWxnlvUqiRc7SbU3HoFn5Elw2aUCJC7jw_z0mxn_j9BBH3pA6DElJ5QQdrruphNWK6nuoRklqioUqekBmhEqqqKqaHmIjlJaE0KkYuwBOuSlpJRJMUPTFbQwmX7A12dX1z--fZ-HRa4MTz5C5w32CZuUgvNmgAbf-GGF55eL81cZogonmCD6YfsCf4whbcANfgLswirEAadhbLbY9A2eTOsbM_jQ73sP0f2laRM82r_H6POb15_m74qLy7fn87OLwgnBVSEUZby01jJmSwZO5QOsM8KAAsEINTWIRoIEqHjNl85yW1oKspLSLStu-TF6ufNuRttB46Afomn1JvrOxK0Oxuu_O71f6S9h0ooLxWuRBc_2ghi-jpAG3fnkoG1ND2FMmuVRRFaC3KJP_0HXYYx9Pk-zmnJGqaIkU893lMsfliIs75ahRN-mqXOa-leamX3y5_Z35O_4MnC6A258C9v_m_T7D4ud8ic6Qq97 |
CitedBy_id | crossref_primary_10_1007_s10096_023_04627_4 crossref_primary_10_3389_fmed_2023_1215246 crossref_primary_10_1021_acs_analchem_4c02105 crossref_primary_10_1097_CCE_0000000000001109 crossref_primary_10_1016_j_ajog_2022_10_001 crossref_primary_10_1002_jmv_28381 crossref_primary_10_1002_cti2_1468 crossref_primary_10_1016_j_chom_2022_11_016 |
Cites_doi | 10.1186/s12879-021-05886-2 10.1016/S0140-6736(20)30566-3 10.1016/j.jinf.2020.11.024 10.1038/s41598-021-92497-1 10.1093/cid/ciab686 10.1128/JCM.00075-21 10.1093/cid/ciaa1285 10.1093/cid/ciaa1196 10.1016/j.jaci.2020.09.018 10.1186/s13054-020-03398-0 10.1038/s41467-020-19057-5 10.1016/j.lfs.2020.117788 10.1093/cid/ciaa1054 10.1093/cid/ciaa1338 10.1038/s41467-021-23494-1 10.1016/j.healun.2020.03.012 10.1016/j.jinf.2021.06.020 10.1038/s41598-021-86500-y 10.1016/j.jmoldx.2020.10.007 10.1007/s40265-020-01421-w 10.1093/jac/dkab093 10.1080/07853890.2022.2031274 10.1016/j.jviromet.2021.114411 10.1016/j.diagmicrobio.2021.115595 10.1093/cid/ciab394 10.1093/cid/ciaa1315 10.1093/ofid/ofab509 10.1016/j.jcv.2022.105166 |
ContentType | Journal Article |
Copyright | 2022 The Authors. published by Wiley Periodicals LLC. 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. 2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. This article is protected by copyright. All rights reserved. |
Copyright_xml | – notice: 2022 The Authors. published by Wiley Periodicals LLC. – notice: 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. – notice: 2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: This article is protected by copyright. All rights reserved. |
CorporateAuthor | PREDINMUN-COVID Group the PREDINMUN‐COVID Group |
CorporateAuthor_xml | – name: PREDINMUN-COVID Group – name: the PREDINMUN‐COVID Group |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
DOI | 10.1002/jmv.27989 |
DatabaseName | Wiley-Blackwell Open Access Collection Wiley-Blackwell Backfiles (Open access) Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Genetics Abstracts Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Genetics Abstracts CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | CARDEÑOSO DOMINGO et al |
EISSN | 1096-9071 |
EndPage | 5270 |
ExternalDocumentID | 10_1002_jmv_27989 35811284 JMV27989 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Observational Study |
GrantInformation_xml | – fundername: The work of Emilia Roy Vallejo has been funded by a Rio‐Hortega grant CM19/00149 from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and co‐funded by The European Regional Development Fund (ERDF) “A way to make Europe”. The sponsor has not had any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WIN WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
ID | FETCH-LOGICAL-c4439-491235bbb22b52ec9089bca4ae9e4201a7e4d8e8ee6373fcb3b5b1e8688cf63b3 |
IEDL.DBID | 33P |
ISSN | 0146-6615 |
IngestDate | Tue Sep 17 20:55:54 EDT 2024 Sat Aug 17 00:40:15 EDT 2024 Thu Oct 10 22:02:18 EDT 2024 Thu Nov 21 21:19:57 EST 2024 Sat Sep 28 08:21:16 EDT 2024 Sat Aug 24 01:02:25 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | COVID-19 poor outcome SARS-CoV-2 disease severity viremia |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. Open access. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4439-491235bbb22b52ec9089bca4ae9e4201a7e4d8e8ee6373fcb3b5b1e8688cf63b3 |
Notes | Senior authorship Laura Cardeñoso Domingoand Emilia Roy Vallejo contributed equally to this study. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 These authors have contributed equally This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.27989 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.27989 |
PMID | 35811284 |
PQID | 2713211910 |
PQPubID | 105515 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9349374 proquest_miscellaneous_2688086404 proquest_journals_2713211910 crossref_primary_10_1002_jmv_27989 pubmed_primary_35811284 wiley_primary_10_1002_jmv_27989_JMV27989 |
PublicationCentury | 2000 |
PublicationDate | November 2022 |
PublicationDateYYYYMMDD | 2022-11-01 |
PublicationDate_xml | – month: 11 year: 2022 text: November 2022 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: London – name: Hoboken |
PublicationTitle | Journal of medical virology |
PublicationTitleAlternate | J Med Virol |
PublicationYear | 2022 |
Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
References | 2021; 8 2021; 21 2022; 152 2021; 23 2021; 147 2020; 80 2020; 39 2020; 323 2020; 11 2021; 72 2021; 73 2021; 59 2021; 76 2021; 12 2021; 11 2022 2020; 73 2020; 395 2020; 24 2022; 74 2020; 254 2022; 54 2021; 83 2022; 300 2022; 102 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 Wang W (e_1_2_9_8_1) 2020; 323 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 |
References_xml | – volume: 102 issue: 3 year: 2022 article-title: Duration of SARS‐CoV‐2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID‐19: a cohort study publication-title: Diagn Microbiol Infect Dis – volume: 83 start-page: 38 issue: 3 year: 2021 article-title: SARS‐CoV‐2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load publication-title: J Infect – volume: 80 start-page: 1929 year: 2020 end-page: 1946 article-title: Immune therapy, or antiviral therapy, or both for COVID‐19: a systematic review publication-title: Drugs – volume: 74 start-page: 218 issue: 2 year: 2022 end-page: 226 article-title: SARS‐CoV‐2 RNAemia predicts clinical deterioration and extrapulmonary complications from COVID‐19 publication-title: Clin Infect Dis – volume: 76 start-page: 1962 issue: 8 year: 2021 end-page: 1968 article-title: Clinical efficacy and safety of remdesivir in patients with COVID‐19: a systematic review and network meta‐analysis of randomized controlled trials publication-title: J Antimicrob Chemother – volume: 152 year: 2022 article-title: Usefulness of real‐time RT‐PCR to understand the kinetics of SARS‐CoV‐2 in blood: a prospective study publication-title: J Clin Virol – volume: 21 start-page: 184 year: 2021 article-title: SARS‐CoV‐2 RNA in plasma samples of COVID‐19 affected individuals: a cross‐sectional proof‐of‐concept study publication-title: BMC Infect Dis – volume: 59 start-page: e0007521 issue: 7 year: 2021 article-title: Sars‐cov‐2 E gene variant alters analytical sensitivity characteristics of viral detection using a commercial reverse transcription‐PCR assay publication-title: J Clin Microbiol – volume: 72 start-page: e690 issue: 10 year: 2021 end-page: e691 article-title: Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection in blood of critically ill patients publication-title: Clin Infect Dis – volume: 12 start-page: 1 issue: 1 year: 2021 end-page: 17 article-title: SARS‐CoV‐2 RNAemia and proteomic trajectories inform prognostication in COVID‐19 patients admitted to intensive care publication-title: Nat Commun – volume: 323 start-page: 1843 issue: 18 year: 2020 end-page: 1844 article-title: Detection of SARS‐CoV‐2 in different types of clinical specimens publication-title: JAMA – volume: 72 start-page: e291 issue: 9 year: 2021 end-page: e295 article-title: High frequency of SARS‐CoV‐2 RNAemia and association with severe disease publication-title: Clin Infect Dis – volume: 73 start-page: e799 issue: 3 year: 2021 end-page: e802 article-title: Severe acute respiratory syndrome coronavirus 2 RNA in plasma is associated with intensive care unit admission and mortality in patients hospitalized with coronavirus disease 2019 publication-title: Clin Infect Dis – volume: 74 start-page: 1525 issue: 9 year: 2022 end-page: 1533 article-title: Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes publication-title: Clin Infect Dis – volume: 11 start-page: 7163 issue: 1 year: 2021 article-title: The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID‐19 patients publication-title: Sci Rep – volume: 254 year: 2020 article-title: The role of biomarkers in diagnosis of COVID‐19—a systematic review publication-title: Life Sci – volume: 11 start-page: 5493 issue: 1 year: 2020 article-title: SARS‐CoV‐2 viral load is associated with increased disease severity and mortality publication-title: Nat Commun – volume: 147 start-page: 72 issue: 1 year: 2021 end-page: 80 article-title: IL‐6 serum levels predict severity and response to tocilizumab in COVID‐19: an observational study publication-title: J Allergy Clin Immunol – volume: 24 start-page: 1 issue: 1 year: 2020 end-page: 13 article-title: Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID‐19 publication-title: Crit Care – volume: 73 start-page: e2995‐ issue: 9 year: 2021 article-title: SARS‐CoV‐2 RNA in serum as predictor of severe outcome in COVID‐19: A retrospective cohort study publication-title: Clin Infect Dis – volume: 8 year: 2021 article-title: Blood SARS‐CoV‐2 RNA load predicts outcome • OFID • 1 SARS‐CoV‐2 blood RNA load predicts outcome in critically ill COVID‐19 patients publication-title: Open Forum Infect Dis – volume: 395 start-page: 1054 issue: 10229 year: 2020 end-page: 1062 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study publication-title: The Lancet – volume: 300 year: 2022 article-title: Evaluation of two RT‐PCR techniques for SARS‐CoV‐2 RNA detection in serum for microbiological diagnosis publication-title: J Virol Methods – volume: 39 start-page: 405 issue: 5 year: 2020 end-page: 407 article-title: COVID‐19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal publication-title: J Heart Lung Transplant – volume: 23 start-page: 10 issue: 1 year: 2021 end-page: 18 article-title: Dynamics of blood viral load is strongly associated with clinical outcomes in coronavirus disease 2019 (COVID‐19) patients publication-title: J Mol Diagn – year: 2022 – volume: 73 start-page: 2890 year: 2020 article-title: Highly sensitive quantification of plasma severe acute respiratory syndrome coronavirus 2 RNA sheds light on its potential clinical value publication-title: Clin Infect Dis – volume: 83 start-page: 381 year: 2021 end-page: 412 article-title: Lower respiratory tract and plasma SARS‐CoV‐2 RNA load in critically ill adult COVID‐19 patients: relationship with biomarkers of disease severity publication-title: J Infect – volume: 11 start-page: 1 issue: 1 year: 2021 end-page: 11 article-title: Detection of SARS‐CoV‐2 RNA in serum is associated with increased mortality risk in hospitalized COVID‐19 patients publication-title: Sci Rep – volume: 54 start-page: 524 issue: 1 year: 2022 end-page: 540 article-title: Emerging COVID‐19 variants and their impact on SARS‐CoV‐2 diagnosis, therapeutics and vaccines publication-title: Ann Med – ident: e_1_2_9_20_1 doi: 10.1186/s12879-021-05886-2 – ident: e_1_2_9_3_1 doi: 10.1016/S0140-6736(20)30566-3 – ident: e_1_2_9_6_1 doi: 10.1016/j.jinf.2020.11.024 – ident: e_1_2_9_7_1 doi: 10.1038/s41598-021-92497-1 – ident: e_1_2_9_16_1 doi: 10.1093/cid/ciab686 – ident: e_1_2_9_25_1 – ident: e_1_2_9_34_1 doi: 10.1128/JCM.00075-21 – ident: e_1_2_9_11_1 doi: 10.1093/cid/ciaa1285 – ident: e_1_2_9_10_1 doi: 10.1093/cid/ciaa1196 – ident: e_1_2_9_4_1 doi: 10.1016/j.jaci.2020.09.018 – ident: e_1_2_9_13_1 doi: 10.1186/s13054-020-03398-0 – ident: e_1_2_9_12_1 doi: 10.1038/s41467-020-19057-5 – ident: e_1_2_9_5_1 doi: 10.1016/j.lfs.2020.117788 – ident: e_1_2_9_9_1 doi: 10.1093/cid/ciaa1054 – ident: e_1_2_9_18_1 doi: 10.1093/cid/ciaa1338 – ident: e_1_2_9_2_1 – ident: e_1_2_9_24_1 – ident: e_1_2_9_30_1 doi: 10.1038/s41467-021-23494-1 – ident: e_1_2_9_26_1 doi: 10.1016/j.healun.2020.03.012 – ident: e_1_2_9_32_1 doi: 10.1016/j.jinf.2021.06.020 – ident: e_1_2_9_17_1 doi: 10.1038/s41598-021-86500-y – ident: e_1_2_9_19_1 doi: 10.1016/j.jmoldx.2020.10.007 – ident: e_1_2_9_27_1 doi: 10.1007/s40265-020-01421-w – ident: e_1_2_9_29_1 doi: 10.1093/jac/dkab093 – ident: e_1_2_9_33_1 doi: 10.1080/07853890.2022.2031274 – ident: e_1_2_9_22_1 – volume: 323 start-page: 1843 issue: 18 year: 2020 ident: e_1_2_9_8_1 article-title: Detection of SARS‐CoV‐2 in different types of clinical specimens publication-title: JAMA contributor: fullname: Wang W – ident: e_1_2_9_23_1 doi: 10.1016/j.jviromet.2021.114411 – ident: e_1_2_9_28_1 doi: 10.1016/j.diagmicrobio.2021.115595 – ident: e_1_2_9_31_1 doi: 10.1093/cid/ciab394 – ident: e_1_2_9_14_1 doi: 10.1093/cid/ciaa1315 – ident: e_1_2_9_15_1 doi: 10.1093/ofid/ofab509 – ident: e_1_2_9_21_1 doi: 10.1016/j.jcv.2022.105166 |
SSID | ssj0008922 |
Score | 2.4684412 |
Snippet | Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a... Early kinetics of SARS-CoV-2 viral load (VL) in plasma determined by quantitative reverse-transcription polymerase chain reaction (RT-PCR) was evaluated as a... Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 5260 |
SubjectTerms | Adult Cohort analysis COVID-19 COVID-19 - diagnosis disease severity Hospitalization Humans Mortality Patients Polymerase chain reaction poor outcome Prospective Studies Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Viremia Virology |
Title | Relevant SARS‐CoV‐2 viremia is associated with COVID‐19 severity: Prospective cohort study and validation cohort |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.27989 https://www.ncbi.nlm.nih.gov/pubmed/35811284 https://www.proquest.com/docview/2713211910 https://search.proquest.com/docview/2688086404 https://pubmed.ncbi.nlm.nih.gov/PMC9349374 |
Volume | 94 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5BD4gL5Z-UggziwCV0azuxDadq26ogFaourLhFdjIrtlKz1W53z32EPiNPwozzA6sKCYlLFMkTxfKMPWOPv28A3vjSG-VsSLPK51zCDFPHtyy0QadLOdA6YmGORubzd7t_wDQ5HzosTMMP0R-48cyI6zVPcB8WO79JQ8_OV--kcZbBe7RLiPANddKvwtY1GQRaCVLyQVnHKjSQO_2X677oRoB5857kn_FrdECHm__V9ftwr407xV5jKA_gFtYP4c5xm1l_BKtTBprTMIvR3uno59X1cDampxQrWhPPp15MF8K3qsRK8PGtGH4Zf9wnoV0nyL8il8F7L07msw69Kbj67vxSRApb4etKkFlPmyJObdtj-HZ48HV4lLY1GdJSa04aOwbXhhCkDJnEktOGofTao0NNwYQ3qCuLFjFXRk3KoEIWdtHm1paTXAX1BDbqWY3PQGhTadrcVJnPvY6BKksanGR2oipZJvC6005x0VBvFA3JsixoBIs4gglsd3or2tm3oBbaYzNz3SCBV30zzRtOhvgaZ0uSoR7Rdk4PdAJPGzX3f2FOOPbbCZg1A-gFmJN7vaWe_ojc3E5pCvjoy7fRAP7e8eLT8Ti-bP276HO4Kxl9EaGQ27BxOV_iC7i9qJYvo_H_ArdHCrc |
link.rule.ids | 230,315,782,786,887,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB7RIgEXoDwXChjUQy9LU9u7thGXKm2VlqatmjbitrJ3HRGkblDS5MxP6G_sL2HG-4CoQkLislrJs1rL87TH8w3Ahs2tEka7OClsSi3MfGzoloVU3sicd6QMtTC9gTr-qnf3CCbnc1MLU-FDtAdupBnBXpOC04H01m_U0O-Xi49cGW1W4K5MURCpgEOctnZYmyqHgLYgRi-UNLhCHb7VfrrsjW6FmLdvSv4ZwQYXtP_o_yb_GB7WoSfbqWRlDe748gnc69fJ9aewOKNac1xpNtg5G9z8vO5OhvjkbIFm8XJs2XjGbM1NXzA6wWXdk-HBLhJtG4Yu1lMnvE_sdDppCjgZNeCdXrGAYstsWTCU7HHVx6keewYX-3vn3V5ct2WIcykpb2yovtY5x7lLuM8pc-hyK603XmI8YZWXhfba-1QoMcqdcInb9jrVOh-lwonnsFpOSv8SmFSFxP1NkdjUyhCrEqXyo0SPRMHzCD407Ml-VOgbWYWzzDNcwSysYATrDeOyWgFnOILbbAKv60Twvh1G1aF8iC39ZI40OCPc0cmOjOBFxef2LwQLR647ArUkAS0BwXIvj5TjbwGe2wiJMR9-uRkk4O8Tzw77w_Dy6t9J38H93nn_KDs6OP7yGh5wKsYIlZHrsHo1nfs3sDIr5m-DJvwCcBsO3w |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIlVceD9SChjEgUvo1nYSG07Vblct0LLqwqq3yI4dsZWarXa7e-Yn8Bv5Jcw4D1hVSEhcokieKJbnaY_nG4DXpjCZ0MrGiTMptTDzsaZbFjLzWha8J2WohTkcZydnanBAMDnv21qYGh-iO3AjzQj2mhT80pW7v0FDzy9Wb3mmld6AmxLDcALOF2LUmWGl6xQCmoIYnVDSwgr1-G736bozuhZhXr8o-WcAGzzQ8M5_zf0u3G4CT7ZfS8o9uOGr-7B13KTWH8DqlCrNcZ3ZeP90_PP7j_5sgk_OVmgUL6aGTRfMNLz0jtH5Let_nhwNkGhPM3SwnvrgvWOj-awt32TUfnd-xQKGLTOVYyjX07qLUzP2EL4OD770D-OmKUNcSElZY03VtdZazm3CfUF5Q1sYabz2EqMJk3nplFfepyITZWGFTeyeV6lSRZkKKx7BZjWr_BNgMnMSdzcuMamRIVIlysyXiSqF40UEr1ru5Jc19kZeoyzzHFcwDysYwU7Lt7xRvwWO4CaboOt6EbzshlFxKBtiKj9bIg3OCPdzsicjeFyzufsLgcKR444gWxOAjoBAuddHqum3AM6thcSID798EwTg7xPPPxxPwsv2v5O-gK3RYJh_Ojr5-BRucarECGWRO7B5NV_6Z7CxcMvnQQ9-ASoIDYU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relevant+SARS%E2%80%90CoV%E2%80%902+viremia+is+associated+with+COVID%E2%80%9019+severity%3A+Prospective+cohort+study+and+validation+cohort&rft.jtitle=Journal+of+medical+virology&rft.au=Carde%C3%B1oso+Domingo%2C+Laura&rft.au=Roy+Vallejo%2C+Emilia&rft.au=Zurita+Cruz%2C+Nelly+D.&rft.au=Chicot+Llano%2C+Marta&rft.date=2022-11-01&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=94&rft.issue=11&rft.spage=5260&rft.epage=5270&rft_id=info:doi/10.1002%2Fjmv.27989&rft.externalDBID=10.1002%252Fjmv.27989&rft.externalDocID=JMV27989 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |